Will Pharma End Up Paying For The Infrastructure Bill?

Or can industry thread the donut hole and prevent government price negotiations from becoming a part of the legislative tsunami?

United States Capitol Building at sunset - Washington, DC, USA - Image

The pharma industry has barely had time to lick its wounds from enhanced Medicaid rebates being included in the just-passed COVID relief bill, and now it faces the prospect of more of the same: popular legislation that incorporates price controls.

House Speaker Nancy Pelosi delivered the bad news during a 23 March press briefing: HR3 could be part of a...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Pricing Debate

More from Market Access